Sarepta Therapeutics (SRPT) Cash from Operations (2010 - 2026)
Sarepta Therapeutics' quarterly Cash from Operations came in at 202683000.0 in Q1 2026, up 65.26% year-on-year from 122644539.8 in Q1 2025, and down 254.48% quarter-over-quarter from 131206000.0 in Q4 2025.
Sarepta Therapeutics has reported Cash from Operations for 17 years, with the latest figure at 202683000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Operations rose 65.26% year-over-year to 202683000.0; the trailing twelve-month figure through Mar 2026 stood at 175275000.0 (up 132.03% YoY), and the FY2025 full-year result was 205479000.0, changed 0.15% from the prior year.
- Cash from Operations for Q1 2026 stood at 202683000.0, down from 131206000.0 in the prior quarter.
- The five-year high for Cash from Operations was 261337000.0 in Q2 2025, with the low at 583437000.0 in Q1 2025.
- Average Cash from Operations over 5 years is 84722823.53, with a median of 70699000.0 recorded in 2024.
- Year-over-year, Cash from Operations plunged 215.05% in 2022 and surged 1649.01% in 2025.
- Tracing SRPT's Cash from Operations over 5 years: stood at 92392000.0 in 2022, then soared by 40.84% to 54657000.0 in 2023, then surged by 268.41% to 92046000.0 in 2024, then jumped by 42.54% to 131206000.0 in 2025, then plunged by 254.48% to 202683000.0 in 2026.
- The last three Cash from Operations figures came in at 202683000.0 (Q1 2026), 131206000.0 (Q4 2025), and 14585000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | -202.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -202.68 Mn |
| Mar 31, 2026 | -202.68 Mn |
| Dec 31, 2025 | 131.21 Mn |
| Dec 31, 2025 | 131.21 Mn |
| Sep 30, 2025 | -14.59 Mn |
| Sep 30, 2025 | -14.59 Mn |
| Jun 30, 2025 | 261.34 Mn |
| Jun 30, 2025 | 261.34 Mn |
| Mar 31, 2025 | -583.44 Mn |
| Mar 31, 2025 | -583.44 Mn |
| Dec 31, 2024 | 92.05 Mn |
| Dec 31, 2024 | 92.05 Mn |
| Sep 30, 2024 | -70.70 Mn |
| Sep 30, 2024 | -70.70 Mn |
| Jun 30, 2024 | 14.94 Mn |
| Jun 30, 2024 | 14.94 Mn |
| Mar 31, 2024 | -242.08 Mn |
| Mar 31, 2024 | -242.08 Mn |
| Dec 31, 2023 | -54.66 Mn |
| Dec 31, 2023 | -54.66 Mn |
| Sep 30, 2023 | -114.71 Mn |
| Sep 30, 2023 | -114.71 Mn |
| Jun 30, 2023 | -122.23 Mn |
| Jun 30, 2023 | -122.23 Mn |
| Mar 31, 2023 | -209.40 Mn |
| Mar 31, 2023 | -209.40 Mn |
| Dec 31, 2022 | -92.39 Mn |
| Dec 31, 2022 | -92.39 Mn |
| Sep 30, 2022 | -64.96 Mn |
| Sep 30, 2022 | -64.96 Mn |
| Jun 30, 2022 | -66.82 Mn |
| Jun 30, 2022 | -66.82 Mn |
| Mar 31, 2022 | -101.18 Mn |
| Mar 31, 2022 | -101.18 Mn |
| Dec 31, 2021 | -29.33 Mn |
| Dec 31, 2021 | -29.33 Mn |
| Sep 30, 2021 | -124.33 Mn |
| Sep 30, 2021 | -124.33 Mn |
| Jun 30, 2021 | -109.15 Mn |
| Jun 30, 2021 | -109.15 Mn |
| Mar 31, 2021 | -180.37 Mn |
| Mar 31, 2021 | -180.37 Mn |
| Dec 31, 2020 | -174.54 Mn |
| Dec 31, 2020 | -174.54 Mn |
| Sep 30, 2020 | -238.19 Mn |
| Sep 30, 2020 | -238.19 Mn |
| Jun 30, 2020 | -107.60 Mn |
| Jun 30, 2020 | -107.60 Mn |
| Mar 31, 2020 | 627.79 Mn |
| Mar 31, 2020 | 627.79 Mn |
| Dec 31, 2019 | -163.80 Mn |
| Dec 31, 2019 | -163.80 Mn |
| Sep 30, 2019 | -67.43 Mn |
| Sep 30, 2019 | -67.43 Mn |
| Jun 30, 2019 | -79.00 Mn |
| Jun 30, 2019 | -79.00 Mn |
| Mar 31, 2019 | -146.23 Mn |
| Mar 31, 2019 | -146.23 Mn |
| Dec 31, 2018 | -122.42 Mn |
| Dec 31, 2018 | -122.42 Mn |
| Sep 30, 2018 | -113.32 Mn |
| Sep 30, 2018 | -113.32 Mn |
| Jun 30, 2018 | -117.25 Mn |
| Jun 30, 2018 | -117.25 Mn |
| Mar 31, 2018 | -35.67 Mn |
| Mar 31, 2018 | -35.67 Mn |
| Dec 31, 2017 | -31.06 Mn |
| Dec 31, 2017 | -31.06 Mn |
| Sep 30, 2017 | -57.90 Mn |
| Sep 30, 2017 | -57.90 Mn |
| Jun 30, 2017 | -85.15 Mn |
| Jun 30, 2017 | -85.15 Mn |
| Mar 31, 2017 | -57.89 Mn |
| Mar 31, 2017 | -57.89 Mn |
| Dec 31, 2016 | -81.23 Mn |
| Dec 31, 2016 | -81.23 Mn |
| Sep 30, 2016 | -60.62 Mn |
| Sep 30, 2016 | -60.62 Mn |
| Jun 30, 2016 | -43.28 Mn |
| Jun 30, 2016 | -43.28 Mn |
| Mar 31, 2016 | -60.69 Mn |
| Mar 31, 2016 | -60.69 Mn |
| Dec 31, 2015 | -31.27 Mn |
| Dec 31, 2015 | -31.27 Mn |
| Sep 30, 2015 | -46.31 Mn |
| Sep 30, 2015 | -46.31 Mn |
| Jun 30, 2015 | -28.53 Mn |
| Jun 30, 2015 | -28.53 Mn |
| Mar 31, 2015 | -43.35 Mn |
| Mar 31, 2015 | -43.35 Mn |
| Dec 31, 2014 | -25.45 Mn |
| Dec 31, 2014 | -25.45 Mn |
| Sep 30, 2014 | -35.32 Mn |
| Sep 30, 2014 | -35.32 Mn |
| Jun 30, 2014 | -39.50 Mn |
| Jun 30, 2014 | -39.50 Mn |
| Mar 31, 2014 | -28.27 Mn |
| Mar 31, 2014 | -28.27 Mn |
| Dec 31, 2013 | -17.82 Mn |
| Dec 31, 2013 | -17.82 Mn |
| Sep 30, 2013 | -19.88 Mn |
| Sep 30, 2013 | -19.88 Mn |
| Jun 30, 2013 | -12.00 Mn |
| Jun 30, 2013 | -12.00 Mn |
| Mar 31, 2013 | -14.99 Mn |
| Mar 31, 2013 | -14.99 Mn |
| Dec 31, 2012 | -7.16 Mn |
| Dec 31, 2012 | -7.16 Mn |
| Sep 30, 2012 | -7.81 Mn |
| Sep 30, 2012 | -7.81 Mn |
| Jun 30, 2012 | -5.68 Mn |
| Jun 30, 2012 | -5.68 Mn |
| Mar 31, 2012 | -9.05 Mn |
| Mar 31, 2012 | -9.05 Mn |
| Dec 31, 2011 | -5.65 Mn |
| Dec 31, 2011 | -5.65 Mn |
| Sep 30, 2011 | -7.52 Mn |
| Sep 30, 2011 | -7.52 Mn |
| Jun 30, 2011 | -442,000.00 |
| Jun 30, 2011 | -442,000.00 |
| Mar 31, 2011 | -10.07 Mn |
| Mar 31, 2011 | -10.07 Mn |
| Dec 31, 2010 | -1.89 Mn |
| Dec 31, 2010 | -1.89 Mn |
| Sep 30, 2010 | -2.77 Mn |
| Sep 30, 2010 | -2.77 Mn |